Veterinary Medicines

Nobivac DHP lyophilisate and solvent for suspension for injection for dogs

Authorised
  • Canine distemper virus, strain Onderstepoort, Live
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine parvovirus, strain 154, Live
Download as PDF

Product identification

Medicine name:
Nobivac DHP lyophilisate and solvent for suspension for injection for dogs
Nobivac DHP vet.
Active substance:
  • Canine distemper virus, strain Onderstepoort, Live
  • Canine adenovirus 2, strain Manhattan LPV3, Live
  • Canine parvovirus, strain 154, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine distemper virus, strain Onderstepoort, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine adenovirus 2, strain Manhattan LPV3, Live
    10000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain 154, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Norway
Package description:
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials of diluent.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials of diluent.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials of vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials of vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 50 single dose vials. The diluent is packed together with the vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Plastic box containing 10 single dose vials. The diluent is packed together with the vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials of diluent.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials of diluent.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials of vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials of vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 50 single dose vials. The diluent is packed together with the vaccine.
  • Clear, Glass Type I (Ph. Eur.) single vials with halogenobutyl rubber stopper, closed with a colour coded aluminium cap.Cardboard box containing 10 single dose vials. The diluent is packed together with the vaccine.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Intervet International B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Intervet International B.V.
Responsible authority:
  • Norwegian Medical Products Agency
Authorisation number:
  • 05-3333
Date of authorisation status change:
Reference member state:
  • Ireland
Procedure number:
  • IE/V/0161/001
Concerned member states:
  • Netherlands
  • Norway
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 10/10/2024
Download

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.
Norwegian (PDF)
Published on: 10/10/2024
Download

ie-puar-mr-iev0161001-nobivac-dhp-lyophilisate-and-solvent-for-suspensio-en.pdf

English (PDF)
Published on: 25/09/2024
Download